US 9651562
Cathelicidin as novel inflammatory bowel disease marker and therapy for colitis associated intestinal fibrosis
granted A61KA61K2035/115A61K2039/505
Quick answer
US patent 9651562 (Cathelicidin as novel inflammatory bowel disease marker and therapy for colitis associated intestinal fibrosis) held by The Regents of the University of California expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2035/115, A61K2039/505, A61K31/19, A61K35/74